12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Deals

Audentes Therapeutics, ReGenX deal

ReGenX granted Audentes exclusive, worldwide rights to use NAV rAAV8 and rAAV9 vectors to develop and commercialize products to treat X-linked myotubular myopathy and Pompe's disease. ReGenX will receive an undisclosed upfront payment and is eligible for undisclosed milestones and royalties. The vectors comprise recombinant adeno-associated viral (AAV)...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >